Literature DB >> 9120542

Primary brain lymphomas in patients with a prior or concomitant malignancy.

M Reni1, A J Ferreri, M C Zoldan, E Villa.   

Abstract

The increased incidence of second malignancies among cancer survivors is well documented. Thus, differential diagnosis between metastatic spread from a prior malignancy and the occurrence of a new neoplasm should be considered. This is particularly difficult for brain lesions due to their poor prognosis that often discourages diagnostic work-up. In some cases diagnosis of a second primary neoplasm, such as primary central nervous system lymphomas (PCNSL), could change the therapeutic management and the prognosis. About 8% of PCNSL occurs as a second malignancy. Homogeneous and intense tomographic enhancement, deep location of lesions and dramatic response to corticosteroids are suggestive for PCNSL and should be carefully considered before the start of treatment for cerebral lesions. Prognosis and standard management of brain metastases and PCNSL are almost completely different. In addition, while treatment of brain metastases often has a palliative purpose the goal in PCNSL treatment is the cure. Four patients with PCNSL as a second malignancy are reported and literature is reviewed. Diagnosis of PCNSL changes the strategy of treatment which could have a critical therapeutic and prognostic impact.

Entities:  

Mesh:

Year:  1997        PMID: 9120542     DOI: 10.1023/a:1005781815202

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Multifocal cerebral gliomas associated with secondary malignancies.

Authors:  A P Kyritsis; W K Yung; N E Leeds; J Bruner; M J Gleason; V A Levin
Journal:  Lancet       Date:  1992-05-16       Impact factor: 79.321

2.  A case of large cell CNS lymphoma associated with a systemic small cell lymphocytic lymphoma.

Authors:  D E Weissman; B D Kueck; A B Merkow
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

3.  Intracranial histiocytic lymphoma with rheumatoid arthritis.

Authors:  A E Good; R H Russo; B Schnitzer; L Weatherbee
Journal:  J Rheumatol       Date:  1978       Impact factor: 4.666

4.  Imaging patterns of multifocal gliomas.

Authors:  A P Kyritsis; V A Levin; W K Yung; N E Leeds
Journal:  Eur J Radiol       Date:  1993-04       Impact factor: 3.528

5.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

6.  Second malignancies associated with chemotherapeutic agents.

Authors:  R A Kyle
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

7.  Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan.

Authors:  L M DeAngelis
Journal:  Ann Neurol       Date:  1993-03       Impact factor: 10.422

8.  Occurrence of a primary Burkitt-type lymphoma of the central nervous system in an astrocytoma patient. A case report.

Authors:  D Giromini; J Peiffer; T Tzonos
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

9.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.

Authors:  J Y Blay; C Lasset; C Carrie; F Chauvin; B Coiffier; C Gisselbrecht; M Clavel; P Rebattu; M Brunat-Mentigny; T Philip
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more
  3 in total

Review 1.  Primary hypothalamic lymphoma in a patient with systemic lupus erythematosus: case report and review of the literature.

Authors:  Antonella Biasiotta; Alessandro Frati; Maurizio Salvati; Antonino Raco; Maurizio Fazi; Alessandro D'Elia; Giorgio Cruccu
Journal:  Neurol Sci       Date:  2010-06-29       Impact factor: 3.307

Review 2.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

3.  Second malignancies in patients with primary central nervous system lymphoma.

Authors:  Jun Wang; Jose S Pulido; Brian Patrick O'Neill; Patrick B Johnston
Journal:  Neuro Oncol       Date:  2014-06-19       Impact factor: 12.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.